Background: The randomized phase III OAK (a study of atezolizumab compared with docetaxel in participants with locally advanced or metastatic non-small-cell lung cancer [NSCLC] who have failed platinum-containing therapy) trial investigated the anti-programmed cell death ligand 1 (PD-L1) antibody atezolizumab for advanced or metastatic, previously treated, NSCLC. Atezolizumab significantly improved overall survival (OS) compared with docetaxel (hazard ratio [HR], 0.73; 95% confidence interval [CI], 0.62-0.87; P = .0003; median OS, 13.8 vs. 9.6 months, respectively). Patient-reported outcomes (PROs) were collected to evaluate disease-related symptoms and health-related quality of life (HRQoL) to support the finding of a survival benefit.
Patients And Methods: The first 850 patients were randomized to receive atezolizumab (1200 mg every 3 weeks) or docetaxel (75 mg/m every 3 weeks). PROs were collected on day 1 of cycle 1, day 1 of every subsequent cycle, and at the end-of-treatment visit for patients who completed ≥ 1 baseline and 1 postbaseline PRO assessment. The European Organisation for the Research and Treatment of Cancer QoL questionnaire and lung cancer module were used to assess PROs.
Results: Atezolizumab delayed the time to deterioration (TTD) in physical function (HR, 0.75; 95% CI, 0.58-0.98) and role function (HR, 0.79; 95% CI, 0.62-1.00) and numerically improved patients' HRQoL from baseline compared with docetaxel. Atezolizumab also prolonged the TTD in chest pain (HR, 0.71; 95% CI, 0.49-1.05; P = .0823), although both arms showed an objective reduction relative to baseline. Overall, the patients had no clinically significant worsening in treatment-related symptoms, although the scores favored atezolizumab.
Conclusion: These PRO data support the clinical benefit of atezolizumab in patients with previously treated advanced or metastatic NSCLC. Atezolizumab prolonged the TTD of patients' limitations in role and physical functions compared with docetaxel.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.cllc.2018.05.011 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
PSMA-targeted delivery of docetaxel in prostate cancer using small-sized PDA-based micellar nanovectors.
J Control Release
January 2025
Asymmetric Synthesis and Functional Nanosystems Group (Art&Fun), Institute of Chemical Research (IIQ), CSIC-University of Seville, C/ Américo Vespucio 49, 41092 Seville, Spain. Electronic address:
In this study, we present the first comparative analysis of active and passive drug delivery systems for docetaxel (DTX) in prostate cancer using supramolecular self-assembled micellar nanovectors. Specifically, we developed two novel micelles based on polydiacetylenic amphiphiles (PDA) for passive and active targeting. The active targeting micelles were designed with a prostate-specific membrane antigen (PSMA) ligand, ACUPA, to facilitate recognition by PSMA-positive cancer cells.
View Article and Find Full Text PDFContinuous Production of Docetaxel-Loaded Nanostructured Lipid Carriers Using a Coaxial Turbulent Jet Mixer with Heating System.
Molecules
January 2025
Department of Electronic Materials, Devices, and Equipment Engineering, Soonchunhyang University, 22 Soonchunhyang-ro, Shinchang-myeon, Asan-si 31538, Chungcheongnam-do, Republic of Korea.
The continuous synthesis of nanoparticles (NPs) has been actively studied due to its great potential to produce NPs with reproducible and controllable physicochemical properties. Here, we achieved the high throughput production of nanostructured lipid carriers (NLCs) using a coaxial turbulent jet mixer with an added heating system. This device, designed for the crossflow of precursor solution and non-solvent, combined with the heating system, efficiently dissolves solid lipids and surfactants.
View Article and Find Full Text PDFA Retrospective, Single-Center Study Comparing Neoadjuvant ACTHP vs. DCbHP in HER2-Positive Early Breast Cancer Patients.
Cancers (Basel)
January 2025
Department of Oncology, Sheba Medical Center, Ramat Gan 52621, Israel.
Background: Neoadjuvant systemic therapy is the preferred treatment approach for stage II-III HER2-positive breast cancer (BC). Real-life data comparing regimens with or without anthracyclines combined with two HER2 drugs is lacking. We compared the efficacy and toxicity of two commonly used regimens.
View Article and Find Full Text PDFAn Updated Systematic Review and Network Meta-Analysis of First-Line Triplet vs. Doublet Therapies for Metastatic Hormone-Sensitive Prostate Cancer.
Cancers (Basel)
January 2025
Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, 1090 Vienna, Austria.
: The addition of androgen receptor pathway inhibitors (ARPIs) to androgen deprivation therapy (ADT), with or without docetaxel (Doc), is currently recommended for metastatic, hormone-sensitive prostate cancer (mHSPC). Recently, the ARANOTE trial evaluated the efficacy and safety of Darolutamide + ADT in this setting. We aimed to update a network meta-analysis (NMA) of these combination therapies.
View Article and Find Full Text PDFCircular RNA circBNC2 inhibits tumorigenesis by modulating ferroptosis and acts as a nanotherapeutic target in prostate cancer.
Mol Cancer
January 2025
NHC Key Laboratory of Molecular Probes and Targeted Diagnosis and Therapy, Harbin Medical University, Harbin, 150001, China.
Background: Metastasis is a leading cause of cancer-related death in castration-resistant prostate cancer (CRPC) patients. Circular RNAs (circRNAs) have emerged as key regulators of the metastasis of various cancers. However, the functional effects and regulatory mechanisms of circRNAs in metastatic CRPC (mCRPC) remain largely unknown.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!